| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
27,200,000 |
| Market
Cap: |
43.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $1.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases where there is high unmet medical and patient need. Co.'s product candidate, tebipenem pivoxil hydrobromide, is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Co.'s pipeline also includes SPR720, an oral treatment for non-tuberculous mycobacterial infection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
229,741 |
229,741 |
288,002 |
2,224,393 |
| Total Sell Value |
$318,043 |
$318,043 |
$392,013 |
$4,729,239 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
6 |
6 |
12 |
18 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mahadevia Ankit |
|
– • – |
2023-08-28 |
4 |
S |
$1.26 |
$11,390 |
D/D |
(9,040) |
788,792 |
|
-13% |
|
| Shukla Sath |
CEO and President |
• • – |
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
266,000 |
578,517 |
|
- |
|
| Hamed Kamal |
Chief Medical Officer |
• – – |
2023-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
615,957 |
|
- |
|
| Mahadevia Ankit |
CEO and President |
• • – |
2023-02-03 |
4 |
S |
$1.81 |
$22,238 |
D/D |
(12,286) |
797,832 |
|
15% |
|
| Joseph Tamara L |
Chief Legal Officer |
• – – |
2023-02-02 |
4 |
S |
$1.86 |
$6,313 |
D/D |
(3,394) |
324,644 |
|
6% |
|
| Shukla Sath |
Chief Financial Officer |
• – – |
2023-02-02 |
4 |
AS |
$1.83 |
$17,372 |
D/D |
(9,504) |
312,517 |
|
-6% |
|
| Keutzer Timothy |
Chief Operating Officer |
• – – |
2023-02-02 |
4 |
S |
$1.86 |
$6,313 |
D/D |
(3,394) |
327,144 |
|
6% |
|
| Mahadevia Ankit |
CEO and President |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
531,914 |
810,118 |
|
- |
|
| Hamed Kamal |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
265,957 |
475,957 |
|
- |
|
| Joseph Tamara L |
Chief Legal Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
265,957 |
328,038 |
|
- |
|
| Shukla Sath |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
265,957 |
322,021 |
|
- |
|
| Keutzer Timothy |
Chief Operating Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
265,957 |
330,538 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2022-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,190,606 |
|
-28% |
|
| Aquilo Capital, L.p. |
10% Owner |
– – • |
2022-09-22 |
4 |
S |
$2.25 |
$4,279,612 |
I/I |
(1,901,796) |
3,419,435 |
|
14% |
|
| Deshpande Milind |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
31,454 |
|
- |
|
| Tregoning Kathleen |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Vink Patrick V.j.j. |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Jackson Scott Thomas |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Thomas Frank E |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Pottage John C Jr |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Smith Cynthia |
Director |
– • – |
2022-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Hamed Kamal |
Chief Medical Officer |
• – – |
2022-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
210,000 |
210,000 |
|
- |
|
| Shukla Sath |
Chief Financial Officer |
• – – |
2022-08-29 |
4 |
AS |
$0.89 |
$5,378 |
D/D |
(6,017) |
56,064 |
|
115% |
|
| Aquilo Capital, L.p. |
10% Owner |
– – • |
2022-04-26 |
4 |
B |
$5.24 |
$207,971 |
I/I |
39,727 |
5,321,231 |
1.5 |
-78% |
|
| Aquilo Capital, L.p. |
10% Owner |
– – • |
2022-03-30 |
4 |
B |
$8.79 |
$439,420 |
I/I |
50,000 |
5,281,504 |
1.5 |
-91% |
|
135 Records found
|
|
Page 2 of 6 |
|
|
0.07 (4.21%) 
